Nicotine is a naturally occurring pyridine alkaloid from plants of the genus Nicotiana that acts as a full agonist at nicotinic acetylcholine receptors (nAChR) and ranks among the most intensively studied psychoactive substances in modern pharmacology.
- Pyridine alkaloid with a chiral structure; the pharmacologically active enantiomer is (S)-nicotine
- Full nAChR agonist with particular affinity for α4β2 and α7 subtypes in the central and peripheral nervous system
- Primary source is plants of the genus Nicotiana (Solanaceae), with N. rustica being especially potent at up to 18% nicotine content by dry weight
- Rapid pharmacokinetics with pulmonary absorption: onset in the CNS within 7–10 seconds, half-life 1–2 hours
- High addictive potential: neurobiologically, nicotine ranks among the most potent addictive substances known, comparable in the intensity of its reward-system hijacking to heroin or cocaine
What Is Nicotine?
Nicotine (IUPAC: (S)-3-(1-methylpyrrolidin-2-yl)pyridine) is a tertiary amine and bicyclic alkaloid first isolated and characterised from tobacco leaves in 1828 by German chemists Wilhelm Heinrich Posselt and Karl Ludwig Reimann. It belongs to the group of pyridine alkaloids and is biosynthetically assembled from L-ornithine and nicotinic acid via the putrescine–nicotinic acid pathway.
As a secondary plant metabolite, nicotine presumably serves a defensive function in the plant against herbivores and insects — a mechanism explained by its acute neurotoxicity towards invertebrates. In humans, however, the same substance produces a complex pharmacological effect on the central and peripheral nervous system.
| Property | Value |
|---|---|
| IUPAC Name | (S)-3-(1-methylpyrrolidin-2-yl)pyridine |
| Molecular Formula | C₁₀H₁₄N₂ |
| Molecular Weight | 162.23 g/mol |
| CAS | 54-11-5 |
| PubChem CID | 89594 |
| Primary Sources | Nicotiana tabacum, Nicotiana rustica |
Pharmacology: Mechanism of Action
Nicotine acts as a full agonist at nicotinic acetylcholine receptors (nAChR), a family of ligand-gated ion channels (Na⁺/K⁺ and Ca²⁺) expressed in both the central nervous system and at neuromuscular junctions and autonomic ganglia.
Two subtypes are of particular pharmacological relevance:
- α4β2-nAChR: Predominantly expressed in the mesolimbic dopamine system. Activation of this subtype by nicotine leads to dopamine release in the nucleus accumbens — this is considered the central mechanism of addiction development. PET imaging studies have shown that nicotine produces pronounced α4β2 occupancy even at very low concentrations (Brody et al., 2006, Arch Gen Psychiatry).
- α7-nAChR: Widely distributed in the cortex and hippocampus, modulates glutamate release and cognitive processes. This subtype is the subject of active research in the context of neurodegenerative diseases.
Beyond this primary receptor binding, nicotine induces a cascade of neurotransmitter releases: dopamine (reward), noradrenaline (alertness, heart rate), acetylcholine (cognition), serotonin, and β-endorphin. This broad profile explains the subjectively experienced effects of relaxation, enhanced concentration, and mood elevation.
With chronic exposure, a paradoxical receptor up-regulation occurs: although nicotine activates the receptors and causes short-term desensitisation, the total number of nAChR in the tissue increases. This mechanism is substantially involved in the development of tolerance and dependence (Benowitz et al., 2009).
Pharmacokinetics
The pharmacological effects of nicotine depend strongly on the route of administration, which determines the speed and extent of bioavailability:
| Route of Administration | Bioavailability | Onset |
|---|---|---|
| Pulmonary (smoking) | ~80% | 7–10 seconds |
| Nasal (rapé / snuff) | ~50–70% | 10–60 seconds |
| Oral (snus, chewing gum) | ~20–40% | Minutes |
| Transdermal (patch) | ~10–30% | Hours |
The plasma half-life of nicotine is approximately 1–2 hours, which is why the subjective effects are relatively short-lived — a factor that contributes to frequent repeated administration. The primary metabolite cotinine, by contrast, has a half-life of 16–20 hours and therefore serves in medicine as a biomarker for nicotine exposure.
Metabolism occurs primarily via the hepatic enzyme CYP2A6. Genetic polymorphisms of this enzyme explain inter-individual differences in processing speed and may influence addiction risk (Malaiyandi et al., 2005, Clin Pharmacol Ther). Nicotine crosses both the blood–brain barrier and the placental barrier.
Plant Sources
Nicotiana tabacum
The commercially cultivated standard tobacco. Nicotine content in the leaves typically ranges between 1 and 3% of dry weight, with considerable variation depending on preparation method and variety. N. tabacum is the basis of virtually all industrial tobacco products.
Nicotiana rustica
Known by indigenous names such as "Mapacho" (Amazonia) or "rustica tobacco," N. rustica is considered the most pharmacologically potent known Nicotiana species. Its nicotine content amounts to 6–18% of dry weight — depending on the analytical method and growing conditions, in some cases 5–10 times higher than N. tabacum.
N. rustica is an integral component of ceremonially used tobacco preparations in indigenous cultures of South America. It forms the basis of many rapé formulations (ceremonial snuffs), in which it is combined with plant ash additives and other medicinal plants. Due to the high alkaloid content, even small quantities may trigger intense physiological responses; informed handling is absolutely essential.
Other Sources
Several species within the Solanaceae (nightshade family) contain nicotine in measurable but pharmacologically negligible traces: tomatoes (Solanum lycopersicum): ~100 ng/g fresh weight; aubergines (Solanum melongena): ~100 ng/g; peppers (Capsicum annuum): ~7–9 ng/g. These amounts are well below any physiologically relevant threshold.
Clinical Significance
Neurobiologically, nicotine is considered one of the most addictive substances known. The rapid onset, short half-life, and intense dopamine activation in the mesolimbic system create the classic conditioning loop characteristic of substance use disorders. The WHO classifies tobacco dependence as "Tobacco Use Disorder" (ICD-10: F17) and emphasises in its Global Tobacco Epidemic Report 2023 that tobacco continues to rank among the leading preventable causes of death worldwide.
Therapeutic applications of nicotine are currently limited primarily to smoking cessation (nicotine replacement therapy: patches, chewing gum, nasal spray, inhaler). The efficacy of these approaches is well-established, although long-term abstinence rates remain moderate.
In addition, active research is ongoing into α7-nAChR agonists in Alzheimer's dementia (cognitive neuroprotection) and in ADHD (attention modulation). To date, however, these approaches have not achieved clear breakthroughs in clinical development; the body of evidence remains exploratory.
Safety Profile
- Acute toxicity: The oral LD₅₀ in humans is cited in the literature at approximately 0.5–1 mg/kg body weight. In an adult (70 kg), this corresponds to a potentially lethal dose of approximately 35–70 mg — a figure that may become relevant with improper handling of highly concentrated extracts or N. rustica products.
- Cardiovascular: Nicotine increases heart rate and blood pressure, causes vasoconstriction, and is contraindicated in pre-existing cardiovascular conditions.
- Pregnancy: Nicotine crosses the placental barrier and is associated with foetal developmental impairments, increased risk of premature birth, and possible long-term neurobiological consequences for the child.
- Interactions: Particular caution is warranted with concurrent use of MAO inhibitors (potentially dangerous sympathomimetic potentiation), certain SSRIs, and insulin therapy (nicotine may affect insulin sensitivity).
Nicotine in the amama Context
Within the amama.space range, nicotine is relevant exclusively in the context of rapé — a ceremonial snuff from indigenous Amazonian traditions that contains Nicotiana rustica as a core ingredient. Given the high alkaloid content of this species, an informed and respectful approach is essential.
Further information on effects, application, and context can be found in our Rapé Guide and in the article Rapé Experience.
amama does not sell pure nicotine products, conventional tobacco products, or vape products. Rapé is the only context in which nicotine plays a role within our range.
Common Myths About Nicotine
Myth 1: "Nicotine causes cancer."
This statement is not scientifically accurate. Nicotine itself is not carcinogenic according to current research. The carcinogenic properties of tobacco smoke are attributable to combustion products — in particular polycyclic aromatic hydrocarbons (PAHs), nitrosamines, and other toxic pyrolysis products. Nicotine contributes to addictive potential, not to carcinogenesis.
Myth 2: "Nicotine only occurs in tobacco."
Incorrect. As outlined in the section on plant sources, nicotine is detectable in trace amounts in numerous Solanaceae species — including tomatoes, peppers, and aubergines. The quantities are pharmacologically insignificant, but demonstrate the widespread distribution of this alkaloid within the plant family.
Myth 3: "Nicotine without smoking is harmless."
This simplification is misleading. While forgoing combustion does eliminate the inhalation toxicity of smoke, addictive potential and cardiovascular effects are retained with every form of administration. Nicotine replacement products are considerably less harmful than smoking, but by no means risk-free — particularly in heart disease, during pregnancy, or with long-term use.
References
- Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;(192):29–60. doi:10.1007/978-3-540-69248-5_2
- Brody AL et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63(8):907–915.
- Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77(3):145–158.
- WHO. Report on the Global Tobacco Epidemic 2023. World Health Organization, Geneva.
- PubChem. Nicotine. CID 89594. https://pubchem.ncbi.nlm.nih.gov/compound/89594
Related Compound Profiles
Last updated: April 2026. This article is for informational purposes only and does not constitute medical advice. Not a medicinal product. Always consult qualified medical professionals regarding health-related questions.